Literature DB >> 11896604

Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine).

Saori Sato1, Naoya Fujita, Takashi Tsuruo.   

Abstract

3-Phosphoinositide-dependent protein kinase-1 (PDK1) plays a central role in activating the AGC subfamily of protein kinases. In particular, PDK1 plays an important role in the regulation of Akt/PKB survival pathway by phosphorylating Akt on Thr308. Here we show that UCN-01 (7-hydroxystaurosporine), a drug now in clinical trials and with a unique fingerprint pattern, induced dephosphorylation and inactivation of Akt, resulting in the turn-off of the survival signals and the induction of apoptosis. Further analysis revealed that UCN-01-mediated Akt inactivation was caused by inhibiting upstream Akt kinase PDK1 (IC50=33 nM) both in vitro and from cells, but not by suppressing Akt itself or phosphatidylinositide-3-OH kinase. UCN-01-induced PDK1 inhibition was also observed in in vivo murine and human tumor xenografts. Overexpression of active form of Akt diminished the cytotoxic effects of UCN-01, suggesting that UCN-01 may in part exert its cytotoxicity by inhibiting PDK1-Akt survival pathway. Because UCN-01 has already proved to have potent anti-tumor activity in vivo, PDK1-Akt survival pathway is a new, attractive target for cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896604     DOI: 10.1038/sj.onc.1205225

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  52 in total

1.  Involvement of FKHR-dependent TRADD expression in chemotherapeutic drug-induced apoptosis.

Authors:  Susumu Rokudai; Naoya Fujita; Osamu Kitahara; Yusuke Nakamura; Takashi Tsuruo
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

2.  Akt/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transition.

Authors:  Kazuhiro Katayama; Naoya Fujita; Takashi Tsuruo
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

3.  PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01.

Authors:  Crissy Dudgeon; Peng Wang; Xiameng Sun; Rui Peng; Quanhong Sun; Jian Yu; Lin Zhang
Journal:  Mol Cancer Ther       Date:  2010-10-26       Impact factor: 6.261

Review 4.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

Review 5.  Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.

Authors:  Sophie Park; Nicolas Chapuis; Jérôme Tamburini; Valérie Bardet; Pascale Cornillet-Lefebvre; Lise Willems; Alexa Green; Patrick Mayeux; Catherine Lacombe; Didier Bouscary
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

6.  Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.

Authors:  Deepa Sampath; Jorge Cortes; Zeev Estrov; Min Du; Zheng Shi; Michael Andreeff; Varsha Gandhi; William Plunkett
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

7.  Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

Authors:  Cynthia X Ma; Shirong Cai; Shunqiang Li; Christine E Ryan; Zhanfang Guo; W Timothy Schaiff; Li Lin; Jeremy Hoog; Reece J Goiffon; Aleix Prat; Rebecca L Aft; Matthew J Ellis; Helen Piwnica-Worms
Journal:  J Clin Invest       Date:  2012-03-26       Impact factor: 14.808

8.  Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation.

Authors:  Qing Zhang; Sufi M Thomas; Vivian Wai Yan Lui; Sichuan Xi; Jill M Siegfried; Huizhou Fan; Thomas E Smithgall; Gordon B Mills; Jennifer Rubin Grandis
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-25       Impact factor: 11.205

9.  PI3K/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate toward sarcoma cells.

Authors:  Uri Elia; Eliezer Flescher
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

10.  Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.

Authors:  Ivana Gojo; Alexander Perl; Selina Luger; Maria R Baer; Kelly J Norsworthy; Kenneth S Bauer; Michael Tidwell; Stephanie Fleckinger; Martin Carroll; Edward A Sausville
Journal:  Invest New Drugs       Date:  2013-02-27       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.